Global market for drugs to treat mental disorders to reach nearly $77.1 billion by 2018

Mental disorders such as schizophrenia, mood disorders, substance abuse, and dementia contribute more to global disease burden than cancer or cardiovascular diseases. During the economic downturn of 2009, the global pharmaceutical industry significantly decreased its investment in new treatments for mental disorders, but the improving economic conditions spurred growth in domestic and foreign investment in the field of mental medication. Improvements in patient security policy, rising disease prevalence, and increasing awareness about mental health issues will shape growth in this market for the foreseeable future.                                                            
 
BCC Research provides an in-depth analysis of the global market for drugs used to treat mental disorders through its report Drugs for Treating Mental Disorders: Technologies and Global Markets. According to the report, this market was valued at $70.1 billion in 2012 and is estimated to have declined slightly to nearly $69 billion in 2013. BCC Research projects the market to grow to nearly $77.1 billion by 2018, and register a five-year compound annual growth rate of 2.3% from 2013 to 2018.

RSS Feeds – Pharmaceuticals

  Use this report to:

• Gain an overview of the global market for drugs used to treat mental disorders.
• Analyze global market trends, with data from 2011 and 2012, estimates for 2013, and projections of CAGRs through 2018.
• Assess information regarding new drug development in the mental health segment, existing products on the market, and a detailed analysis of the competitive environments.
• Review comprehensive company profiles of major players in this market.

SAMPLE FIGURE

GLOBAL REVENUE OF DRUGS USED IN MENTAL DISORDERS, 2011-2018

($ MILLIONS)

 

To order your copy of this report (or any of its chapters) or to download the complimentary introduction chapter, click here.

Global mental health pharmaceutical industry to reach $88.3bn by 2015

The global mental health pharmaceutical industry was estimated at $80.5 billion in 2010. By 2015, this market is likely to reach $88.3 billion, at a compound annual growth rate (CAGR) of 1.9% from 2010 to 2015.

Learn about the current state of pharmaceutical markets, and new drug development in the mental health segment, existing products on the market, and a detailed analysis of the competitive environments, including new potential markets and trends...

Use this report to:

• Gain a comprehensive view of the current state of the pharmaceutical marketplace, and new drug developments in the mental health segment
• Identify and evaluate new markets, trends, and developments in the mental health pharmaceutical industry, including potential new geographic markets and emerging products such as memory enhancement drugs
• Asses the competitive environment, the status and strategies of major market participants, and whether your company is appropriately positioned to capture market share
• Understand the drivers and challenges that affect growth and development in each submarket or category of psychiatric drugs.

To provide further information about this report we offer a Complimentary Introduction, available from our Website. To download, simply click here, go to the Table of Contents tab, add the complimentary introduction to your cart, and confirm your order.

RSS Feeds – Pharmaceuticals

GLOBAL MENTAL HEALTH PHARMACEUTICAL INDUSTRY BY DRUG CATEGORY, 2009-2015

($ BILLIONS)